Although the majority of new drug candidates suffer from poor solubility and bioavailability, oral solid dosage forms remain the preferred route of administration due to their ease of use and convenience for patients and caregivers. In recent years, numerous drugs formulated as amorphous solid dispersions (ASDs) have been successfully commercialized, confirming the effectiveness of these technologies for enhancing the dissolution of challenging APIs.
Topics covered in the article:
-
Addressing Solubility Issues
-
Benefits of ASDs
-
Two Leading ASD Technologies
-
Maintaining the Metastable Form
-
Facilitating ASD Development and Manufacturing
-
Greater Understanding for Rational Design